Safety, efficacy and pharmacokinetics of interferon alfa-2B and ribavirin in children with chronic hepatitis C.

被引：0
|
作者：
Bunn, S [1 ]
Kelly, D [1 ]
Murray, KF [1 ]
Shelton, M [1 ]
Olson, A [1 ]
Mieli-Vergani, G [1 ]
Zambas, D [1 ]
Gupta, SK [1 ]
Glue, P [1 ]
机构：
[1] Spri, Kenilworth, NJ USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
763
引用
收藏
页码：350A / 350A
页数：1
相关论文
共 50 条
  • [41] Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    Poynard, T
    McHutchison, J
    Manns, M
    Trepo, C
    Lindsay, K
    Goodman, Z
    Ling, MH
    Albrecht, J
    GASTROENTEROLOGY, 2002, 122 (05) : 1303 - 1313
  • [42] Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting
    Kumar, D
    Wallington-Beddoe, C
    George, J
    Lin, R
    Samarasinghe, D
    Liddle, C
    Farrell, GC
    MEDICAL JOURNAL OF AUSTRALIA, 2003, 178 (06) : 267 - 271
  • [43] Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
    Poynard, T
    McHutchison, J
    Davis, GL
    Esteban-Mur, R
    Goodman, Z
    Bedossa, P
    Albrecht, J
    HEPATOLOGY, 2000, 32 (05) : 1131 - 1137
  • [44] Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT: Final results
    Jacobson, IM
    Russo, MW
    Lebovics, E
    Esposito, S
    Tobias, H
    Klion, F
    Brown, RS
    Dieterich, D
    Brass, C
    GASTROENTEROLOGY, 2002, 122 (04) : A627 - A627
  • [45] Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions
    Khakoo, S
    Glue, P
    Grellier, L
    Wells, B
    Bell, A
    Dash, C
    Murray-Lyon, I
    Lypnyj, D
    Flannery, B
    Walters, K
    Dusheiko, GM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (06) : 563 - 570
  • [46] Single-dose pharmacokinetics of interferon alfa2b in children with chronic hepatitis C.
    Gonzalez-Peralta, RP
    Glue, P
    Hodik, M
    Davis, GL
    Lau, JY
    HEPATOLOGY, 1999, 30 (04) : 264A - 264A
  • [47] TREATMENT WITH RECOMBINANT INTERFERON ALFA-2B IN CHILDREN WITH CHRONIC HEPATITIS-C
    HELLER, S
    CERDAN, L
    GONZALEZ, J
    VELASCO, M
    HEPATOLOGY, 1994, 19 (04) : I72 - I72
  • [48] Effect of cirrhosis on the pharmacokinetics and pharmaco-dynamics of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
    Laughlin, M
    Jen, JF
    Gupta, S
    Chung, C
    Heft, S
    Affrime, MB
    Albrecht, JK
    Hajian, G
    HEPATOLOGY, 2001, 34 (04) : 424A - 424A
  • [49] Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C
    Wirth, S
    Pieper-Boustani, H
    Lang, T
    Ballauff, A
    Kullmer, U
    Gerner, P
    Wintermeyer, P
    Jenke, A
    HEPATOLOGY, 2005, 41 (05) : 1013 - 1018
  • [50] Sustained antiviral response with consensus interferon (CIFN)plus ribavirin or interferon alfa-2b (IFN alfa-2b) plus ribavirin in treatment-naive subjects with chronic hepatitis C. A pilot study.
    Sjogren, MH
    Holtzmuller, K
    Smith, M
    Sjogren, R
    HEPATOLOGY, 2002, 36 (04) : 311A - 311A
12345